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Abstract. This paper presents an Integrated
Product Development (IPD) based model to specifically
develop bio-medical micro-electro-mechanical-systems
(BioMEMS). The concurrent engineering model is based
on the IPD model phases, which are presented and for-
mulated by the Integration DEFinition (IDEF) model-
ling language. To evaluate the IPD model, a case study
concerning the development of a BioMEMS device for
a deep brain stimulation (DBS) system was investig-
ated. By following the relevant mechanisms and con-
trols in the model, a design concept of a wireless head-
mounted DBS implant integrated with a drug delivery
system (DDS) was conceived. The contribution of this
paper is the IDEF model, which provides a road map
to the product development team members in order to
take a concurrent engineering approach to develop Bio-
MEMS. The qualitative feedback received from the iden-
tified stakeholders, together with the quality of the case
study employed, namely, an integrated DBS and DDS
solution, indicate a degree of evidence that the model
provides a sound basis in this direction.
Keywords: Integrated Product Development,
Design Tools and Methods, Product Miniaturization,
BioMEMS
1 Introduction
Physical movement and brain functioning are naturally
taken for granted unless a physiological impairment re-
stricts their function. Conditions or symptoms such
as tremors, dystonia, obsessive-compulsive disorder, de-
pression, or severe chronic pains definitely reduce the
quality of life by restricting these abilities. It is repor-
ted by CBC (2010), that one of the most severe diseases
which affects both motion and the brain is Parkinson’s
disease; a progressive neurological disorder exhibited by
seven to ten million people worldwide. It is caused by
a deficiency of dopamine-producing cells and affects the
motor and coordination functions in a human being.
The monitoring and reduction of tremors associated
with Parkinson’s disease can be performed through con-
trolled stimulation via a pulse generator device, which
can be configured via an external portable program-
mer. The electrodes, which are embedded in the af-
fected brain zones, receive these controlled pulses and
distribute them to the nervous system in order to prop-
erly actuate the parts of the body which exhibit abnor-
mal motor activity. This process is known as DBS. In
DBS, electrodes are placed in the thalamus or in the
subthalamic nucleus or globus pallidus. According to
Klaubert (2005), the electrodes are connected by means
of wires to the impulse generator implanted under the
skin of the chest below the collarbone. A schematic dia-
gram of the DBS setup is illustrated in Figure 1.
Figure 1: Schematic diagram of a Deep Brain Stimulator
(WebMD, 2015).
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Once activated, the device sends continuous electrical
pulses to the targeted brain areas, modifying the beha-
viour of the brain’s neural network that is responsible
for the motor symptoms. Da Silva (2013) states that
this medical procedure is better than thalamotomy or
pallidotomy, because DBS can be configured according
to the needs of the patient and can be applied without
affecting other parts of the brain. DBS is usually sup-
ported by means of a prescribed daily drug intake.
Micro-Electro-Mechanical Systems, or MEMS, is a
technology that in its most general form, can be
defined as miniaturized electro-mechanical elements (i.e.
devices and structures) that are made using micro-
fabrication techniques. Meanwhile, BioMEMS have
emerged as a subset of MEMS devices for applications
in biomedical research and medical micro-devices. They
are used for various applications such as drug deliv-
ery, tissue engineering and bio-sensor development. The
study carried out by Da Silva (2013) confirmed that the
BioMEMS technology market has been growing extens-
ively in the last couple of years.
In the recent years, automatic drug delivery has been
a very active research field in the pharmaceutical in-
dustry. Drug intake could be better controlled if the
patient has an implantable BioMEMS device that can
be actuated in such a way that the drug is released
periodically when needed. Although BioMEMS devices
provide solutions to challenges faced in the medical sec-
tor, they also give rise to a number of issues at the
micro-scale level. Alexander, Rogers, Sheehan and Will-
son (2004) highlighted that one of the most critical is-
sues that has to be taken into consideration when using
MEMS devices is bio-compatibility. Any device to be
implanted in the body for an extended period of time
should not include toxic materials or fluids or pose the
risk of causing damage to any local tissue. Another im-
portant factor to be addressed is hermeticity, such that
the functionality of the device is not compromised by its
surroundings. For these reasons, designing BioMEMS is
not always an easy task. One should consider various
factors in the early stages of the product development,
that might affect the final design. The product develop-
ment of BioMEMS based medical devices has a complex
nature since it involves multidisciplinary stakeholders
such as physicians and engineers, often with conflicting
views (Santos, 2013).
In addition, the development of medical devices is
highly influenced by the regulatory requirements and
business considerations (Santos, 2013). Despite these
challenges, a study by Linehan, Pate´-Cornell and Yock
(2007) reveals that there was little data on the devel-
opment process of medical technologies. The findings
in this study have also been confirmed by an extensive
literature review carried out six years later by Santos
(2013). The IPD model is one proposal for the im-
plementation of concurrent engineering in the product
development process (Andreasen & Hein, 2000). This
model follows the idea of parallelizing tasks which are
carried out by various streams within the product de-
velopment process in order to allow for concurrent con-
sideration of the problems. In view of this context, the
overall goal of this work was to develop an IPD based
model specifically targeted for the development of Bio-
MEMS. Given the complexity to develop a BioMEMS
device which requires multidisciplinary expertise, mod-
elling of the process will greatly help IPD stakeholders
to visualise the information flow from the concept to
the product launch. To this end, in this paper the In-
tegration DEFinition (IDEF) modelling language is de-
ployed to portray the various features characterising the
information flow in such an IPD model.
Based upon this introduction, the rest of this paper
is organised as follows. Section 2 reviews concurrent
engineering approaches as well as existing products re-
lated to DBS, which are readily available on the market.
The developed IPD model is then presented in Section
3, with particular emphasis made on the product design
phase. The subsequent section focuses on the imple-
mentation of the developed model via a case study of
an integrated DBS system equipped with a drug delivery
mechanism. Results of an evaluation carried out with a
sample of subjects, consisting mainly of IPD stakehold-
ers, patients and neurosurgeons, are presented in Sec-
tion 5. The strengths and weaknesses of the proposed
model together with those of the case-study solution are
discussed in Section 6. Further research directions are
also proposed. Finally Section 7 draws key conclusions,
highlighting the contribution made in this paper.
2 Related Work
2.1 Product Development Models
This section first reviews generic product development
models, followed by specific ones, in particular those re-
lated to medical devices. Amongst several existing mod-
els, the model proposed by Eppinger and Ulrich (2011)
starts by the planning phase followed by concept devel-
opment, system level design, detail design, testing and
refinement and production ramp-up. At each phase,
marketing, design and production activities are iden-
tified. Similarly to the model presented in Andreasen
and Hein (2000), these two models are characterized by
a matrix which chronologically shows the different devel-
opment phases in relation to the functional core discip-
lines (Scha¨tz, 2006). Common to all the aforementioned
models is the fact that the information flow between
the different phases is not modelled formally using the
IDEF modelling language but rather by means of block
diagrams and flowcharts (Fenech & Farrugia, 2014). In
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this work, the IDEF0, which is one class of IDEF mod-
elling languages, was chosen to model the IPD as it is
specifically designed to represent the activities, actions
and decisions of a ‘system’. Furthermore, apart from its
simplicity, the major benefit of using IDEF0 is that it
applies dynamic information into the model to handle
problems involving parallel activities (Fenech & Farru-
gia, 2014).
As will be described later on in Section 3, the model
presented in this paper is closer to the original standard
IDEF0 modelling language, with the introduction of a
data connectivity type to reflect the stakeholders input.
An extensive literature review of product development
models, specifically targeted for medical devices, was
carried out by Santos (2013). Over thirty models were
reviewed, none of which specifically treated BioMEMS.
Watty and Binz (2005) presented a proposal for MEMS
design methodology based on the VDI guideline 2206
(Beuth, 2004). Even though this methodology covers
the whole life-cycle of a component, it does not spe-
cifically mention very important aspects for BioMEMS,
which are the need for safety, risk assessment and qual-
ity considerations.
Due to the novelty and nature of the products, ma-
terials, risk and quality assessment and manufacturing
technologies, the development of BioMEMS requires a
structured development process. As explained in Smith
(1997), BioMEMS need not only efficient components
but also their correct and reliable interaction to fulfill
the function of the entire system. Despite this, the above
review suggests that there exists no definite method-
ology tailored specifically for the development of Bio-
MEMS. Many disciplines use approved methodologies
for product development such as the VDI-guidelines for
mechanics as explained by Reichl (1994) and mechat-
ronics as discussed by Beuth (2004), or widely auto-
mated design procedures in microelectronics. The mod-
els reviewed are aimed at serving as a guideline to im-
plement product development related principles in cer-
tain disciplines and do not sufficiently include the inter-
disciplinary and system interrelations demanded in the
development of BioMEMS.
2.2 Review of Deep Brain Stimulation Devices
There are various solutions available on the market for
DBS systems. Current systems involve the need for DBS
to use electrical impulses to stimulate a target area in
the brain which affects movement by altering the activ-
ity in that region. The procedure does not destroy any
brain tissue and stimulation can be changed or stopped
at any time. Some of the solutions are readily available
on the market, like MedtronicTM devices, while others
are still at a concept stage. It is vital to mention that
undergoing DBS surgery does not mean that one stops
daily drug intake.
Current solutions offer various advantages such as the
fact that DBS is reversible and the patient can stop
treatment at any time. DBS can be customized to the
patient’s requirements in such a way that the electrical
stimulation is adjustable according to the patient’s re-
sponse to medications. On the other hand, failure of the
battery could result in the device not working beyond its
estimated time limit. As a result, this would entail the
need for another minor surgery to replace the battery.
Also, if the frequency and the intensity of the pulses re-
quired by the patient are increased, these could result
in the need to change the battery before its expected
life-time.
Most common DBS systems generally have the pulse
generator system placed in the chest area and which
is connected via an extension wire to the electrode re-
gion in the skull area. The literature review presented
in Cutajar (2014) shows that the device is susceptible
to have broken leads or wires, especially the extension
wire. This is most likely to occur in slim people. Pos-
sible studies could exploit alternative ways to avoid this
failure. Research has been made on ways how to extend
the battery lifetime of a DBS system. For this reason,
seeking to further investigate battery longevity would
be a major requirement demanded by the stakeholders.
Current DBS systems are relatively modular, how-
ever, if one simply focuses on their function and their
additional potential capabilities, one can easily note that
it is quite limited in terms of flexibility. This can be
mainly noted since its purpose is solely intended for the
treatment of uncontrolled diseases or movements. In
addition, through an existing literature research (Obeso
et al., 2001; Parkinson’s Disease Foundation, 2015) it
was revealed that while medication is significantly re-
duced after surgery, the body still needs to be sustained
by the daily medication dosage. In addition, the liter-
ature survey presented in Cutajar (2014) showed that
the integration of these two systems (DBS and DDS)
together is in its infancy. DBS and DDS are presented
as individual solutions for different purposes.
Through quantitative data gathering from a market
research, it was discovered that the currently available
pulse generator devices embedded in the chest area are
quite large in size (Cutajar, 2014). This possibly results
in certain level of discomfort to the patient. The pos-
sibility of miniaturization of an integrated DBS system
was especially highlighted by young patients (Cutajar,
2014). Based on existing research current systems the
current minimum size is approximately 54 mm by 54 mm
and the target size is to go down to 25 mm by 25 mm
which is approximately half the size of current system.
The aspect of miniaturisation combined with the lack
of integration of the DBS with DDS mentioned above,
provided scope and motivation for the research team to
seek an innovative solution.
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Figure 2: General block diagram of the developed IDEF0 model.
3 An IDEF0 Model for BioMEMS
From the identification of the market gap and the re-
quirements set out by several stakeholders, it is im-
portant to formulate a concurrent engineering approach
to develop BioMEMS. This new approach needs to
make use of a model which provides means for new
marketing and sales opportunities while resulting in a
planned manufactured strategy to produce high quality
products, which conform to the biomedical standards
and directives set out by the medical sector.
The model being proposed (refer to Figure 2) incor-
porates both the IPD model phases such as the invest-
igation of the need and product principle by Andreasen
and Hein (2000) and the IDEF0 modelling language
principles. It must be mentioned that the phases in
Figure 2 can also be perceived as functions within an
IDEF0 modelling context. Andreasen and Hein’s model
has been employed in this research, since it integrates all
the pillars from the very initial recognition of the need
to the final execution. On the other hand, a shortcom-
ing of this model and which is addressed in this work,
lies in the fact that no explicit reference is made to qual-
ity considerations. Through extensive market research
it was established that quality is significantly important
when developing BioMEMS (Cutajar, 2014).
IDEF0 was chosen as it offers a structured represent-
ation of the different functions of a system and it cap-
tures the activities, decisions and actions taken. The
tool acknowledges that a successful systems develop-
ment requires input and validation from the users. In
fact, IDEF0 incorporates inputs, outputs, controls and
mechanisms for a specific function (refer to legend in
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Figure 3: IDEF0 model of Phase 3: Product Design.
Figure 2). It must be pointed out that the IDEF0 model
presented in this section was developed and based on the
requirements to market, design and fabricate BioMEMS.
Figure 2 depicts a general overview of the developed
model, consisting of five phases (Phase 1 to Phase 5),
whereby development flows sequentially through these
phases whilst, in each of these phases, development
activity will be taking place both sequentially and con-
currently, involving the three IPD pillars along with
quality. Since the design stage is critical in the overall
IPD model, this paper focuses on Phase 3. This phase
involves important decisions on the preliminary design
solution of a BioMEMS device and is presented in Fig-
ure 3. Further details on the other phases are available
in Cutajar (2014).
Phase 3 focuses on the details of the developed
concept and the means how to actually produce the first
simulation models specifically designed for BioMEMS
(refer to corresponding IDEF0 model in Figure 3). As
can be observed from Figure 3, the inputs of Phase 3
are fed from the outputs of Phase 2. With reference
to Figure 3, ‘market investigation’, ‘preliminary design
solution’ and ‘determining production principles’ are il-
lustrated as concurrent activities in the Andreasen and
Hein’s IPD model under the product design phase. The
fourth function regarding quality was added in the pro-
posed IPD model.The primary goal of this phase is to
define further design details and ensure that the final
detailed design solution is augmented with the stake-
holders’ feedback and requirements. This is defined in
order to enhance the product specifications and set the
BioMEMS concepts for the manufacturing and assembly
systems. The preliminary design together with the ini-
tial considerations of manufacturing systems give rise to
the possible ideas and concepts of how the system will
be produced.
The mechanisms defined in Phase 3 include, the cost
benefit analysis of the new BioMEMS device over cur-
rent systems and the modular functional deployment
(MFD) which is closely related to Quality Function
Deployment (QFD). In addition, a number of design
modelling tools (e.g. CAD) and design analysis tools
(e.g. DFX) and evaluation tools (e.g. decision matrices
and material selection tools) feature as mechanisms in
Phase 3. To detect any potential weaknesses in the
design and subsequently in the process, the Failure
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Mode and Effect Analysis (FMEA) tool is also included
as a mechanism in this phase. Similarly as in Phase 2,
another important mechanism relates to the collabora-
tion tools which aid to facilitate communication between
the different IPD stakeholders. For instance, collabor-
ation tools can be used to collectively investigate the
market and to determine product principles. At the ini-
tiation of Phase 3, the market research would have been
carried out, whereby this data would have been gathered
and the customer’s needs identified. Other controls also
include the standards for manufacturing within the med-
ical industry such as the bio-compatibility of the chosen
materials which need to abide by the medical standards,
such as the Food and Drug Administration (FDA) and
European Medicines Agency (EMA) standards. This
shall also lead to enhanced concurrency in the devel-
opment of BioMEMS. One of the major outputs is the
need to set out a preliminary design which is carried out
by making use of various CAD software tools. It would
also be ideal if as an output of this phase, one identifies
the possible technologies needed for the production of
the components or systems.
4 Application Case Study
To adopt a user-centred design approach, typical end-
users of the device were involved in the case study.
These included five patients whose age varied between 4
to 60+ years and two neurological surgeons. Due to the
difficulty in accessing BioMEMS and integrated circuit
designers, it was not possible to engage such stakehold-
ers. The study was carried out by organising different
focus groups which were aimed at gathering qualitative
data. The case study revolved around the development
of an integrated DBS and DDS system. The need for
such a system emerged after the patients and the med-
ical specialists highlighted that the patient still needs to
take a daily drug dosage after undergoing surgery. The
clinical need to maintain medication is generally related
only to the non-motor symptoms of the disease. As dis-
cussed in Marek and Antle (2008), specific patients have
also mentioned that the daily dosage imposes a certain
level of dependence on the family members and highly
depends on one’s health. The fact that patients need
to depend on others in order to take their medication is
seen as a reduction of one’s quality of life. This solution
would most likely aid patients who suffer from demen-
tia and similar mental sickness. Many of the risk factors
related to inadequate medication management are more
prevalent in older adults, like for instance the possibil-
ity of mixing prescribed medication which could lead to
serious consequences.
During the design phase it is important to determine
how the product will be configured. It is also important
that the designer keeps into perspective that the chosen
materials conform to the medical standards, in order
to ensure that the final device is bio-compatible due to
the sensitivity of the environment in which it will be
embedded. The various stakeholders were asked about
their requirements, in order to be capable to translate
these into product design specifications. To this end,
a QFD was compiled during phase 2 of the IPD model
(refer to Figure 2). The weight distribution of the QFD
engineering requirement scores revealed that the most
critical requirements of the DBS system include:
• Minimizing the probability of a defective exten-
sion wire between the pulse generator and the elec-
trodes.
• Maximizing the patient’s comfort – this is very im-
portant so as the DBS can be implanted in patients
of all ages, therefore, it is crucial that the design
of the DBS should aim to maximize comfort. This
comes about with the possibility of miniaturizing
the device.
• Maximizing battery longevity – this is one of the
main critical features in the pulse generator. The
better the battery’s capacity, the longer the bat-
tery lifetime. The procedure to replace this requires
a minor surgery. This is something one cannot
do without unless the batteries are rechargeable.
Thus, it is advisable that at this phase of the IPD
model, the latest rechargeable batteries available
on the market are sought, in order to guarantee the
maximum possible lifetime of the system.
• Need for DBS system to be bio-compatible – it is
one of the most important requirements of any med-
ical device which needs to be implanted in the hu-
man body.
The results also showed that 60% of the interviewed
people state that if they had to choose, they would
pick a system which is aesthetically more appealing and
less visible. Based on this analysis, this concept has
to be unobtrusive. Meanwhile, this device also seeks
to incorporate the need for automatic daily drug in-
take, which could ultimately allow the patients to lead
a better lifestyle. A number of concepts were generated
in Phase 3, by means of sketching and other synthesis
tools, namely morphological charts. These concepts in-
cluded a range of different configurations of the DBS im-
plant and the DDS. Relevant stakeholders, in particular
neurosurgeons and engineering personnel were involved
to select the most plausible configuration, through a de-
cision matrix. However, since in the scope of this work
the actual prototype was not developed in a real indus-
trial context, certain mechanisms such as collaboration
tools, were not deployed during the evaluation exercises.
It resulted that the preferred configuration would be a
wireless head mounted DBS implant with a DDS. This
system would be responsible for two functions, primarily
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injecting a designated amount of charge into the human
body by providing a precise amount of output current
or output voltage for the predefined period (architecture
of the DBS is shown in Figure 4(a)).
Figure 4: (a) Block diagram of the integrated DBS with adaptive
power supply control and active charge balancing for both power-
efficient and safe current stimulation (Lee, Park & Ghovanloo,
2013) (b) Architecture of the proposed DDS (Cutajar, 2014).
Secondly, it releases the right amount of drug at the
right time needed by the body (refer to Figure 4(b)).
These functions may be programmed and configured
wirelessly through the use of an external device via a coil
(Cutajar, 2014). The same system is used to recharge
the in-packaged battery which is chosen to be a non-
cytotoxic rechargeable one. An external rechargeable
battery energizes the implanted device, which is placed
behind the ear similarly to cochlear implants and hear-
ing aids, via an inductive power transmission charger.
This would be designed to be removable once the in-
ternal DBS system is fully charged. The external bat-
tery of the programmer and charger can then be ener-
gized ‘oﬄine’ without being worn by the patient. This
presents a well-designed aesthetic, safe and modular
device to the end-user and it is quite unnoticeable.
5 Evaluation
As part of the evaluation strategy a number of stake-
holders were questioned in relation to the validity of the
IPD model as well as the developed device solution. Due
to the sensitivity of the subject and the limited avail-
ability of stakeholders in the local sector, the sample
of respondents was relatively small. In fact only four-
teen participants took part in the evaluation process.
The results focus on a qualitative rather than quant-
itative data collection. The participants who volun-
teered in the evaluation exercise consisted of four aca-
demics coming from three related fields of study (mater-
ial processing, neurology and marketing), two neurosur-
geons, one neurophysiologist, five patients of different
age brackets, one member of the European Parkinson’s
Association, and one consultant in a company which
supplies medical products. The participants were asked
a set of questions and presented with the prototype solu-
tion and the IPD model in the case of academics. A
five-point Likert scale was used to measure the parti-
cipants’ attitude to the posed questions. A selection of
the gathered feedback together with sample comments
quoted from different stakeholders coming from different
sectors are provided in Table 1 (on page 8) and Table 2
(on page 9).
6 Discussion
This section discusses the strengths and weaknesses of
the IDEF0 model as well as those of the case study solu-
tion which were identified from the qualitative data col-
lected. The degree of validity of the research results
obtained is also discussed in the last part of this sec-
tion.
6.1 Strengths and Weaknesses of the IDEF0
Model
A number of strengths of the IPD model have been iden-
tified from the qualitative data collected, namely:
• Since the three pillars of IPD are included as activ-
ities in each phases, the proposed IDEF0 model,
reflects concurrent engineering, which automatic-
ally demands an improvement in the communica-
tion between the different departments. In addi-
tion, it emphasizes the vertical integration across
the three IPD pillars in conjunction with quality
considerations (this also includes the risk assess-
ment and safety considerations). This direct rela-
tionship accentuates its importance and intercon-
nection. In addition, such integration ensures that
a product of good quality is being carefully manu-
factured according to the exact requirements of the
stakeholder.
• The investigation of the need in the early stages of
development links to determine the type of product.
This would then set targets for the considerations
of the process type and the quality systems to be
considered. This activity will aid the organisation
to decide whether the project should proceed or put
on hold.
• The model emphasizes the need to consider qual-
ity considerations, safety, risk assessment as well
as the importance of implementing standards and
guidelines since the device has to abide by a high
level of medical standards.
• Activities concerning manufacturing and the pos-
sible available technologies are presented in the very
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early design stages so that any defects or barriers
are highlighted as soon as possible in the design
cycle.
• The model provides a visual representation of the
process flow along the product life-cycle from the
idea initiation stage to the realization which chal-
lenges the inputs and controls.
• The feedback implemented in the model permits to
revert to particular activities during the develop-
ment process. Its importance comes about since a
minor mistake at the development and production
stage could ultimately result in challenges later on
during the product’s life-cycle. This may poten-
tially result in high losses for the company.
On the other hand, one of the major criticisms high-
lighted by the medical team and the business repres-
entatives, was that whereas within the IDEF0 phases,
a parallel flow is emphasized, reflecting concurrency of
IPD, the phases themselves are sequential in nature.
This is attributed to the fact that certain inputs emerge
from previous output activities.
Table 1: IPD Model: Selection of the qualitative evaluation results and average ratings obtained (1:Bad – 5:Good).
Question 1 2 3 4 5 Additional Comments
Do the IPD pillars adopt a holistic
approach and a level of continuity
between phases?
X Marketing and sales are the least important from
the IPD pillars since if one is offering a good
quality product, one does not necessarily need
to market it since patients still believe in the
product and need it. For this reason the sales
factor is not so important when it comes to such
medical products. Having said that, marketing
and sales could be one of the main key barriers
to certain selective patients. Neurosurgeon
The most important pillar is design, as it is the
fundamental fulcrum on which any project kick
starts its process development. Consultant at
a Medical Device Company
What is the level of importance the dif-
ferent solutions (current and new DBS
solution) give to the three IPD pillars
together with the quality factor?
X The most important factors are the following:
a very good design in the initial stages of the
product’s lifecycle, a good manufacturing pro-
cedure, in order to have one of the best solu-
tions on the market, followed by a good qual-
ity product, which abides by the necessary med-
ical standards in this field. The current solution
which is available on the market does not cater
for good integration between these, however the
proposed system takes into account all factors,
and meanwhile, one can still improve the sales
execution. Neurophysiologist
What is the level of importance given
to the vertical integration between the
three IPD pillars and quality factor?
X Vertical integration between the pillars and qual-
ity is missing in the currently available devices,
and encourages the need for further parallelism
between the three pillars and quality, if one needs
to achieve a successful product. Neurosurgeon
What is the practicality of the model
and does this provide enough tools to
address the situation from three differ-
ent IPD pillars together with quality?
X If the mentioned tools and methodology had
to be adopted during the life-cycle of the pro-
cess development, the solution to the device
would be based on the customers’ needs and re-
quirements while ensuring a successful sellable
product. Neurosurgeon
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Table 2: New DBS-DDS Solution: Selection of the qualitative evaluation results and average ratings obtained (1:Bad – 5:Good).
Question 1 2 3 4 5 Additional Comments
To what extent does the new design ad-
dress the market gap?
X The new design offers a safe quality product
which provides a safe mindset to the customer.
Its miniaturized system can make the customer
instantly comfortable. Its size and charging sys-
tem instantly gives a better frame of mind that it
is designed for patients of all ages. This product
highlights the voice of the customer. Patient -
Parkinson’s Disease (Age: 35)
To what extent do the stakeholders be-
nefit from the new design, and how
much does the design address the cur-
rent limitations?
X The main limitations are usually highlighted via
the customer requirements. This was dealt with
efficiently. Neurosurgeon
Main burden is that the patient constantly needs
to remember to take one’s medication. This is
something which was resolved through the use
of the new DBS design. Patient (45 years)
To what extent does the new design ad-
dress the importance for miniaturiza-
tion and that of extended battery life-
time?
X The system definitely presents an improvement
over the current solution. It deals with the main
weaknesses of the systems currently available on
the market and addresses these issues in the
most prominent way. Patient (55 years)
What is the level of importance given
to the new design to address biocom-
patibility and abide by the regulations
and standards for medical devices?
X The new design ensures that the product is of
high quality and abides by the medical stand-
ards and regulations. The material selection was
carefully selected so as to opt for the best solu-
tions. Lecturer in Materials and Metal-
lurgy
How beneficial is the integration of the
pulse generator device and DDS de-
signed as a single system? To what ex-
tent does the device offers design mod-
ularity to patients to make their life
easier?
X The new system is a single device which caters
for different functional solutions, thus offering a
level of modularity to the patient. It would be a
good idea to have the possibility of two separate
solutions. Patient (49 years)
Does the new generated solution
present a challenge to implement such
device in production?
X Manufacturing this device is not too complex.
The most challenging of all is the nature of the
product. The fact that it is a biomedical device,
it needs to conform to certain strict require-
ments. Member-European Parkinson’s As-
sociation
Do you think the new solution will
present a life style improvement?
X Confident that our lives will be improved
drastically. Patient (6 years)
Do you believe that this solution would
be cost effective?
X It will not be a cheap solution especially because
of the integration of the new DDS and working
mechanism of the wireless rechargeable battery.
But it offers a more flexible solution which bet-
ter caters for the patient’s needs. Member-
European Parkinson’s Association
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6.2 Strengths and Weaknesses of the Case
Study Solution
The comments gathered from the focus group shed light
on a number of benefits of the proposed design when
compared to the current design solutions, particularly:
• Improved comfort – a miniaturized solution which
can be directly implanted and fitted into the skull
area, with electrodes that are implanted in either
the subthalamic Nucleus or a section of the globus
pallidus. These brain sites normally play crucial
roles in regulating movement. This presents various
challenges due to the sensitivity and space limita-
tion; however, one of the main benefits is that the
device is much smaller and thinner than the cur-
rently available systems on the market. In addition,
a miniaturised DBS-DDS system will be more ap-
pealing to young patients diagnosed with Parkinson
Disease, thereby increasing the market potential of
the device, given that there is more evidence push-
ing in the direction of an early stimulation approach
(Schuepbach et al., 2013).
• Elimination of the long extension wire which con-
nects the leads to the neuro-stimulator wire from
the skull area to the chest area in the conventional
devices. One of the most frequent failures is due to
the breakage of this wire. This was carefully solved
by omitting this wire and carefully connecting the
electrodes to the DBS system via a short wire in the
skull area itself. The possibility of the wire being
damaged is significantly reduced.
• Increasing battery efficiency – The battery to be
installed into the devices is recharged through an
external charger which transmits power by means
of a coupled coil system which then feeds an on-chip
AC-DC converter. The external charger can be en-
ergized without being mounted on the ear, and then
worn once fully charged. Once charged the external
system can be removed, improving aesthetics and
safety. The internal battery would then feed the
internal devices.
• Less drug intake – since the drug will be delivered in
the local neighbouring affected zones, the drug con-
tent can be less. When implanting the DBS device,
a single surgical intervention is needed. This in-
cludes both the pulse generator and DDS in a single
device. Having these two systems incorporated in
a single system makes it less stressful and painful
for the patient, while giving the patient the benefit
of having two implanted systems.
• Throughout the design and planning, it was made
sure that the stakeholders’ requirements were met.
The project initially focused on the miniaturization
of the device and finding the ways and the means
of improving battery longevity. From the market
research it was highlighted that especially for older
adults, the ability to remain independent depends
on the ability to manage a complicated medication
regime. The idea of designing a DBS system incor-
porated with a DDS not only results in having an
integrated design through a single intervention, but
also proves that the patient could be independent.
The advantages of advanced drug delivery systems
over traditional systems are the ability to deliver a
drug more selectively to a specific site, in a more
accurate way, with less frequent dosage, decreased
variability in the systemic drug concentrations, ab-
sorption that is more consistent with the site and
mechanism of action, and reductions in toxic meta-
bolites.
• The new DBS system could be custom made to
suit the patient’s needs, and equipped with selected
drugs systems. Further studies can be carried out
to explore other possible drug delivery solutions.
On the other hand, the DBS does not cater for all
the symptoms of Parkinson’s disease. While the
patient will gradually reduce the drug content, the
medication will not be stopped completely. For this
reason, the DDS was incorporated within the DBS
design in order to cater for the daily drug intake.
In addition, if either of the systems fails, since the
pulse generator and DDS are combined in a single
device the whole device needs to be removed and
re-implanted. These two systems cannot be man-
aged separately. The major challenge for the pro-
duction and manufacturing perspective is to outline
the production layout of the DBS device which has
the integrated DDS.
6.3 Validity of the Research Results
In order to ensure that the obtained results were reli-
able and realistic it was important to involve as many
respondents as possible. Despite the efforts made, the
number of stakeholders who contributed to the study
was relatively limited. This was mainly due to the sens-
itive nature of the project. Also, local expertise in this
area is quite limited. On the other hand, the involve-
ment of the main team of professionals coming from dif-
ferent sectors gave an added value throughout the course
of the research. The fact that the patients, who have
undergone the DBS surgery, were involved, contributed
to a broad and detailed evaluation. This was heavily
supported by the opportunity to meet a limited num-
ber of neurosurgeons, whose contribution proved to be
highly beneficial. Further discussions with the sales and
production representatives, including both local and for-
eign organisations would have made the analysis more
reliable. The core team was relatively limited to a small
sample of professionals. In future research, it would be a
good potential input to consider increasing the amount
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of team members coming from the different IPD pillars
and the quality sector. This ensures that the degree of
completeness of the model is also validated.
In addition, the research presented in this paper was
focused primarily on the application of the proposed
IPD model on a case study of an integrated DBS-DDS
system from an engineering perspective. Having said
that, to test further the validity of the integrated Bio-
MEMS system from a medical perspective, clinical tests
are required. For instance, the type of drug (e.g. GABA
or L-DOPA) to be delivered and the location of deliv-
ery with respect to the electrical stimulation must be
investigated. This shall shed light on the medical feas-
ibility of having a system, which is able to deliver both
medication and electrical stimuli.
7 Conclusion
BioMEMS technology deals with the integration of di-
verse micro-technologies in complex and highly integ-
rated systems. Thus, BioMEMS require special atten-
tion with respect to their product development and the
wide range of manufacturing technologies which are con-
stantly being developed and updated. The current state
and the requirements of BioMEMS technology, collect-
ively led to the need of a methodology, specifically de-
signed and adopted for it.
In conclusion, the key contribution of this paper lies in
the proposed IPD model aimed at developing BioMEMS
while taking a case study of an integrated DBS-DDS
system as an application. Compared to the state-of-the-
art, the proposed integrated system provides a number
of remarkable benefits. Nevertheless, this is an on-going
process which requires further work in order to validate
the developed IPD model and to assess the effectiveness
of the proposed device solution in a practical scenario.
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